This observational study will target patients with axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA) who have started treatment with bimekizumab, upadacitinib, risankizumab, guselkumab, or a tumour necrosis factor-alpha inhibitor (e.g., adalimumab or etanercept) at NHS hospitals in the United Kingdom. Information from patients' medical records will be collected, and patients will complete surveys about their experiences with their treatment. The study will look at treatment effectiveness from both healthcare professionals' and patients' points of view.
Participant has a clinical diagnosis of axial spondyloarthritis (axSpA) or psoriatic arthritis (PsA).
Participant has been prescribed advanced therapy within one month prior to enrolment in the study, to treat their axSpA or PsA.
Participant is aged 18 years or older at enrolment.
None
Participants will be selected from patients attending NHS hospitals and related healthcare sites targeted across the United Kingdom, including England, Scotland, Wales, and Northern Ireland. These sites are secondary and tertiary care centres where patients with axial spondyloarthritis or psoriatic arthritis are routinely managed by rheumatology services.
Cohort
Other
observational study
Other interventionThis is an observational study based on existing treatments prescribed prior to inclusion. No interventions are given as part of this research.
Number of participants that have achieved Low Disease Activity (LDA) at 12 months.
Number of participants that have achieved Minimal Disease Activity (MDA) at 12 months.
Change from baseline in PROM scores at 12 months.
Click on the lead sponsor to view all of their trials.
